Clinical progress note: Management of the hospitalized patient with medetomidine withdrawal
- 29 September 2026
- journal article
- other
- Published by Wiley in Journal of Hospital Medicine
Abstract
Medetomidine is an ⍺2 adrenergic agonist that has rapidly emerged as an adulterant in the US illicit opioid supply. Clinicians should suspect medetomidine exposure when opioid overdoses respond poorly to naloxone. Medetomidine withdrawal is clinically distinct from opioid and xylazine withdrawal and should be suspected when a patient with opioid withdrawal presents with significant rebound sympathetic activation, including hypertension, tachycardia, tremor, agitation, and refractory vomiting despite opioid agonist treatment. Management requires concurrent treatment of opioid withdrawal, early use of ⍺2 agonists, and escalation to dexmedetomidine infusion for severe cases. Greater access to testing and prospective treatment data are needed.Keywords
This publication has 13 references indexed in Scilit:
- Emergence of Medetomidine in the Illicit Drug Supply: Implications for Emergency Care and Withdrawal ManagementAnnals of Emergency Medicine, 2026
- Recent advances in the identification and quantification of xylazine and medetomidine in biological specimensBioanalysis, 2025
- Severe Fentanyl Withdrawal Associated With Medetomidine Adulteration: A Multicenter Study From Philadelphia, PAJournal of Addiction Medicine, 2025
- Diagnosis and Management of Medetomidine Withdrawal: Clinical Implications of the Shifting Illicit Opioid LandscapeJournal of the Academy of Consultation-Liaison Psychiatry, 2025
- Medetomidine-Associated Opioid Overdoses in Chicago, Illinois: A Report of 3 CasesJournal of Addiction Medicine, 2025
- Medetomidine Infiltrates the US Illicit Opioid MarketJAMA, 2024
- Classics in Chemical Neuroscience: MedetomidineACS Chemical Neuroscience, 2024
- Incidence of Dexmedetomidine Withdrawal in Adult Critically Ill Patients: A Pilot StudyCritical Care Explorations, 2019
- Medetomidine — a novel α2-adrenoceptor agonist: A review of its pharmacodynamic effectsProgress in Neuro-Psychopharmacology and Biological Psychiatry, 1989
- Noradrenaline-induced emesisNeuropharmacology, 1987